Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00879086 · ClinicalTrials.gov registry record · Phase 2

A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer

A Phase 2 study of Breast Cancer, sponsored by Eisai.

Completed
Registry status
Phase 2
Development phase
104
Enrollment target
20
Study locations

NCT00879086 is a Phase 2 study of Breast Cancer that has completed, run by Eisai. The registered enrollment target is 104 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00879086, a Phase 2 study of Breast Cancer, has completed, sponsored by Eisai.

COMPLETED
Registry status
Phase 2
Development phase
104 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study in patients with advanced breast cancer is to compare the incidence and severity of neuropathy adverse events for the two treatment groups (eribulin versus ixabepilone) using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 3.0) grading.

Conditions Studied

Breast Cancer

Interventions

  • DRUG Ixabepilone
  • DRUG Eribulin Mesylate

Study Locations (20)

Florida

  • Comprehensive Cancer Care Specialist of Boca - Boca Raton
  • Robert R. Carroll, MD, PA - Gainesville
  • Hematology Oncology Associates - Lake Worth
  • Medical Specialists of the Palm Beaches - Lake Worth
  • Ocala Oncology Center - Ocala
  • Hematology Oncology Associates of Treasure Coast - Port Saint Lucie
  • Oncology and Hematology Associates of West Broward - Tamarac

California

  • Healing Hands Oncology and Medical Care - Hawthorne
  • University of Southern California - Los Angeles
  • Comprehensive Cancer Center - Palm Springs

Louisiana

  • Hematology and Oncology Specialists - Marrero
  • Metairie Institute of Comprehensive Health - Metairie
  • Hematology and Oncology Specialists - New Orleans

Illinois

  • Hematology Oncology Associates of Illinois - Chicago
  • Decatur Memorial Hospital - Decatur

Maryland

  • Maryland Oncology Hematology, PA - Columbia
  • Washington County Hospital - Hagerstown

Arizona

  • Northern AZ Hematology and Oncology Associates - Sedona

Indiana

  • Central Indiana Cancer Centers - Indianapolis

Iowa

  • Heartland Oncology Hematology - Council Bluffs

Trial Details

FieldValue
Enrollment Target 104 participants
Start Date 2009-03-31
Est. Completion 2014-04-30
Phase Phase 2

Sponsor

Eisai

287 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00879086

The ClinicalTrials.gov registry entry for NCT00879086 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Ixabepilone is the first listed.

NCT00879086 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Florida, California, Louisiana.

Frequently Asked Questions

What is clinical trial NCT00879086 about?

NCT00879086 is a clinical study titled "A Study Comparing Eribulin Mesylate and Ixabepilone in Causing or Exacerbating Neuropathy in Participants With Advanced Breast Cancer". The purpose of this study in patients with advanced breast cancer is to compare the incidence and severity of neuropathy adverse events for the two treatment groups (eribulin versus ixabepilone) using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE version 3.0) gr...

What is the current status of trial NCT00879086?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2009-03-31. Estimated completion is 2014-04-30.

What conditions does trial NCT00879086 study?

This clinical trial studies the following conditions: Breast Cancer.

What interventions are being tested in trial NCT00879086?

The interventions under investigation include: Ixabepilone (DRUG), Eribulin Mesylate (DRUG).

Who is sponsoring clinical trial NCT00879086?

This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00879086 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Breast Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Breast Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.